OPKO Health (NASDAQ:OPK) Cut to Sell at StockNews.com

StockNews.com cut shares of OPKO Health (NASDAQ:OPK) from a hold rating to a sell rating in a report published on Wednesday morning.

A number of other analysts have also recently issued reports on OPK. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th.

OPKO Health Price Performance

OPKO Health stock opened at $1.47 on Wednesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company’s 50-day moving average is $1.54 and its 200-day moving average is $1.51. The firm has a market capitalization of $1.00 billion, a PE ratio of -7.74 and a beta of 1.63. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the purchase, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at approximately $313,384,121.19. The trade was a 0.07 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have bought 1,954,255 shares of company stock worth $2,985,105. Company insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

Institutional investors have recently bought and sold shares of the business. FMR LLC increased its holdings in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Algert Global LLC bought a new position in OPKO Health during the 2nd quarter worth $44,000. Orion Portfolio Solutions LLC acquired a new position in OPKO Health in the 3rd quarter valued at $45,000. Private Advisor Group LLC lifted its position in shares of OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 25,000 shares during the period. Finally, World Investment Advisors LLC acquired a new stake in shares of OPKO Health during the 3rd quarter worth $61,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.